The Fly | OKYO

Novel Mechanism of Action: OKYO Pharma's lead candidate, OK-101, employs a unique lipid-conjugated chemerin peptide to target GPCRs, representing a novel therapeutic approach for ocular surface diseases.

Large Addressable Market in DED: The primary target indication, Dry Eye Disease (DED), affects millions globally, presenting a substantial market opportunity for a differentiated and effective new treatment.

Progressed Clinical Development: OK-101 is currently in Phase 2 clinical trials for DED, signifying a significant advancement in the development pipeline and a reduction in early-stage development risk.

Clinical Development Failure Risk: The company's lead product candidates may not succeed in clinical trials, failing to demonstrate efficacy or safety, which could lead to significant delays, increased costs, or discontinuation of development.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, obtaining necessary regulatory approvals from health authorities like the FDA is a complex and uncertain process, with no guarantee that OKYO's product candidates will receive the required marketing authorizations.

Funding and Capital Availability Risk: Developing pharmaceutical products is capital-intensive, and OKYO may need to raise substantial additional capital in the future, which might not be available on favorable terms or at all, potentially leading to delays or cessation of programs.